GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » Earnings Yield (Joel Greenblatt) %

Genprex (Genprex) Earnings Yield (Joel Greenblatt) % : 0.00% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Genprex Earnings Yield (Joel Greenblatt) %?

Genprex's Enterprise Value for the quarter that ended in Mar. 2024 was $-3.40 Mil. Genprex's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-27.81 Mil. Genprex's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Genprex's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

GNPX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10000   Med: 0   Max: No Debt
Current: 909.09

During the past 9 years, the highest Earnings Yield (Joel Greenblatt) of Genprex was 10000.00%. The lowest was -10000.00%. And the median was 0.00%.

GNPX's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -15.57 vs GNPX: 909.09

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Genprex's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Genprex Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Genprex's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Earnings Yield (Joel Greenblatt) % Chart

Genprex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -256.41 -11.85 -85.47 -48.78 -454.55

Genprex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -95.24 -76.34 -270.27 -454.55 -

Competitive Comparison of Genprex's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Genprex's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genprex's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Genprex's Earnings Yield (Joel Greenblatt) % falls into.



Genprex Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Genprexs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-31.076/6.93228
=-448.28 %

Genprex's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.81 Mil.



Genprex  (NAS:GNPX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Genprex Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Genprex's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genprex (Genprex) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » Earnings Yield (Joel Greenblatt) %
Traded in Other Exchanges
Address
3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.
Executives
Catherine M Vaczy officer: EVP & Chief Strategy Officer C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner director, 10 percent owner, officer: Chief Executive Officer P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar officer: Chief Mfgr & Tech Officer 3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker director C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio director 1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr. director 1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman officer: EVP & Chief Operating Officer 16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc. director, 10 percent owner, officer: Chief Executive Officer 1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham officer: Chief Operating Officer 944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth 10 percent owner 6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance 10 percent owner 8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer officer: Chief Financial Officer 1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson director 3001 MEANDERING RIVER COURT, AUSTIN TX 78746

Genprex (Genprex) Headlines

From GuruFocus